Showing posts with label drug safety project. Show all posts
Showing posts with label drug safety project. Show all posts

Monday, May 5, 2014

Implementing Pharmaceutical Serialization and Traceability Perspectives and Investments - The Pew Charitable Trusts

Updated November 29, 2019

You might also be interested in:
Drug Supply Chain Security Act Law and Policies - FDA.org

- - -  the original post follows below  - - -

Implementing Pharmaceutical Serialization and Traceability Perspectives and Investments: - The Pew Charitable Trusts

"The Pew Charitable Trusts’ drug safety project and Booz Allen Hamilton conducted a qualitative assessment in 2013 of stakeholder perspectives on serialization and traceability systems across the U.S. pharmaceutical distribution supply chain. The analysis in the report Implementing a Pharmaceutical Serialization and Traceability System in the United States: Stakeholder Perspectives and Investments offers a high-level snapshot of industry expectations, system preferences, and anticipated investments that can inform implementation of DQSA. "

'via Blog this'

Read The Report:  Implementing a Pharmaceutical Serialization and Traceability System in the United States: Stakeholder Perspectives and Investments (PDF)

Return Home:  The Designated Representative and Exemptee Blog

-------------

The largest selection of Board-approved California Designated Representative online training classes for wholesalers, 3PL, reverse distributors. Earns a training affidavit.
The largest selection of Board-approved California Designated Representative online training classes for wholesalers, 3PL, reverse distributors. Earns a training affidavit.



For Designated Representative license applicants  -  Training programs, courses, classes, seminars:

     California (earn a training affidavit):
     Florida:

For HMDR Exemptee license applicants  -  Training programs, courses, classes, seminars:

     California (earn a training completion certificate):

Custom Search

From SkillsPlus International Inc.